J&J’s prostate cancer drug approved in EU
LONDON (Reuters) – Johnson & Johnson’s prostate cancer drug Zytiga has been approved in the European Union, paving the way for the launch of a new treatment for men whose disease has progressed after chemotherapy, the company said on Wednesday.
September 7th, 2011
Posted in
Drug